Overview

A Study of Lonafarnib With or Without Ritonavir in Patients With HDV

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected with Hepatitis Delta Virus
Phase:
Phase 2
Details
Lead Sponsor:
Eiger BioPharmaceuticals
Treatments:
Lonafarnib
Ritonavir